Skip to main content
SpringerLink
Log in

Epidemiology of Progressive Multiple Sclerosis

  • Chapter
  • First Online:
Book cover Progressive Multiple Sclerosis

  • 1237 Accesses

Abstract

Since the earliest clinical descriptions of multiple sclerosis (MS), it has been recognised that a minority of patients experience slow accumulation, or progression of disability from onset of disease [1]: this phenotype is now commonly termed primary progressive MS (PPMS). However, more commonly patients go on to develop progression only following an initial period of relapses; this is referred to as secondary progressive disease (SPMS) [2]. These two distinct phases of relapses and progression are now thought to reflect the dual pathological processes of neuroinflammation and neurodegeneration which, in part, give rise to the wide clinical phenotype of MS [3]. Although our understanding of MS has made significant advances in recent years, there remains no single definitive diagnostic test or biomarker which accurately reflects the underlying disease process or biology, and as a result our ability to identify and quantify disease progression remains limited [2]. As we enter a new treatment era for MS, including the advent of clinical trials in progressive disease, epidemiological studies remain important in providing insights into the biology and evolution of disability in primary and secondary MS and are also key to the planning of successful interventional studies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Charcot J. Lectures on the diseases of the nervous system (chapter). In: Disseminated sclerosis: its symptomatology. London: New Sydenham Society; 1877. p. 209–17.

    Google Scholar 

  2. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.

    Article  CAS  PubMed  Google Scholar 

  4. Andersson PB, Waubant E, Gee L, Goodkin DE. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. Arch Neurol. 1999;56(9):1138–42.

    Article  CAS  PubMed  Google Scholar 

  5. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(7):1900–13.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Minderhoud JM, van der Hoeven JH, Prange AJ. Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand. 1988;78(1):10–5.

    Article  CAS  PubMed  Google Scholar 

  7. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain. 1990;113(6):1597–628.

    Article  PubMed  Google Scholar 

  8. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993;116(1):117–34.

    Article  PubMed  Google Scholar 

  9. McDonnell G, Hawkins S. An epidemiologic study of multiple sclerosis in Northern Ireland. Neurology. 1998;50(2):423–8.

    Article  CAS  PubMed  Google Scholar 

  10. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122(4):625–39.

    Article  PubMed  Google Scholar 

  11. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65(12):1919–23.

    Article  PubMed  Google Scholar 

  12. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(3):606–16.

    Article  PubMed  Google Scholar 

  13. Debouverie M, Louis S, Pittion-Vouyovitch S, Roederer T, Vespignani H. Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. J Neurol. 2007;254(10):1370–5.

    Article  CAS  PubMed  Google Scholar 

  14. Koch M, Mostert J, Heersema D, De Keyser J. Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci. 2007;255(1–2):35–41.

    Article  CAS  PubMed  Google Scholar 

  15. Maghzi AH, Etemadifar M, Saadatnia M. Clinical and demographical characteristics of primary progressive multiple sclerosis in Isfahan, Iran. Eur J Neurol. 2007;14(4):403–7.

    Article  CAS  PubMed  Google Scholar 

  16. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology. 2009;73(23):1996–2002.

    Article  PubMed  Google Scholar 

  17. Harding KE, Wardle M, Moore P, et al. Modelling the natural history of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;86(1):13–9.

    Article  PubMed  Google Scholar 

  18. Jena S, Alexander M, Aaron S, et al. Natural history of multiple sclerosis from the Indian perspective: experience from a tertiary care hospital. Neurol India. 2015;63:866–73.

    Article  PubMed  Google Scholar 

  19. Piccolo L, Kumar G, Nakashima I, et al. Multiple sclerosis in Japan appears to be a milder disease compared to the UK. J Neurol. 2015;262(4):831–6.

    Article  CAS  PubMed  Google Scholar 

  20. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology. 1996;46(4):907–11.

    Article  CAS  PubMed  Google Scholar 

  21. Debouverie M, Laforest L, Van Ganse E, Guillemin F. Earlier disability of the patients followed in multiple sclerosis centers compared to outpatients. Mult Scler. 2008;15(2):251–7.

    Article  Google Scholar 

  22. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain. 1989;112(1):133–46.

    Article  PubMed  Google Scholar 

  23. Stankoff B, Mrejen S, Tourbah A, et al. Age at onset determines the occurrence of the progressive phase of multiple sclerosis. Neurology. 2007;68(10):779–81.

    Article  CAS  PubMed  Google Scholar 

  24. McDonnell G, Hawkins S. Clinical study of primary progressive multiple sclerosis in Northern Ireland. J Neurol Neurosurg Psychiatry. 1998;64(4):451–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ribbons KA, McElduff P, Boz C, et al. Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS. PLoS One. 2015;10(6):e0122,686. published online. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0122686

    Article  Google Scholar 

  26. Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology. 2002;59(12):1922–8.

    Article  CAS  PubMed  Google Scholar 

  27. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D, University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59(7):1006–10.

    Article  CAS  PubMed  Google Scholar 

  28. Harding KE, Liang K, Cossburn MD, et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2013;84(2):141–7.

    Article  PubMed  Google Scholar 

  29. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007;356(25):2603–13.

    Article  CAS  PubMed  Google Scholar 

  30. Delalande S, Seze JD, Ferriby D, Stojkovic T, Vermersch P. Late onset multiple sclerosis. Rev Neurol (Paris). 2002;158(11):1082–7.

    CAS  Google Scholar 

  31. Tremlett H, Devonshire V. Is late-onset multiple sclerosis associated with a worse outcome? Neurology. 2006;67(6):954–9.

    Article  PubMed  Google Scholar 

  32. Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill T, Robertson N. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler J. 2012;18(1):45–54.

    Article  CAS  Google Scholar 

  33. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999;122(10):1941–50.

    Article  PubMed  Google Scholar 

  34. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129(3):595–605.

    Article  PubMed  Google Scholar 

  35. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland. J Neurol Neurosurg Psychiatry. 1987;50(5):523–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Leray E, Morrissey S, Yaouanq J, et al. Long-term survival of patients with multiple sclerosis in west France. Mult Scler J. 2007;13(7):865–74.

    Article  CAS  Google Scholar 

  37. Grytten Torkildsen N, Lie S, Aarseth J, Nyland H, Myhr K. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in western Norway. Mult Scler J. 2008;14(9):1191–8.

    Article  CAS  Google Scholar 

  38. Smestad C, Sandvik L, Celius E. Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients. Mult Scler. 2009;15(11):1263–70.

    Article  CAS  PubMed  Google Scholar 

  39. Hader WJ. Disability and survival of multiple sclerosis in Saskatoon, Saskatchewan. Can J Neurol Sci. 2010;37(1):28–35.

    Article  PubMed  Google Scholar 

  40. Kingwell E, van der Kop M, Zhao Y, et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry. 2012;83(1):61–6.

    Article  CAS  PubMed  Google Scholar 

  41. Leray E, Vukusic S, Debouverie M, et al., 2015, Excess mortality in patients with multiple sclerosis starts at 20 years from clinical onset: data from a large-scale French observational study. PLoS One, 10(7): e0132,033. Published online. 10.1371/journal.pone.0132033

  42. Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander MA. Epidemiology of multiple sclerosis: results from a large observational study in the UK. J Neurol. 2015;262(9):2033–41.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Sandi D, Zsiros V, Fvesi J, et al. Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013. J Neurol Sci. 2016;367:329–32.

    Article  PubMed  Google Scholar 

  44. Koch MW, Greenfield J, Javizian O, Deighton S, Wall W, Metz LM. The natural history of early versus late disability accumulation in primary progressive MS. J Neurol Neurosurg Psychiatry. 2014;86(6):615–21.

    Article  PubMed  Google Scholar 

  45. Bergamaschi R, Berzuini C, Romani A, Cosi V. Predicting secondary progression in relapsing-remitting multiple sclerosis: a Bayesian analysis. J Neurol Sci. 2001;189(1–2):13–21.

    Article  CAS  PubMed  Google Scholar 

  46. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler J. 2003;9(3):260–74.

    Article  Google Scholar 

  47. Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129(3):584–94.

    Article  CAS  PubMed  Google Scholar 

  48. Koch M, De Keyser J, Tremlett H. Timing of birth and disease progression in multiple sclerosis. Mult Scler. 2008;14(6):793–8.

    Article  CAS  PubMed  Google Scholar 

  49. Tedeholm H, Skoog B, Lisovskaja V, Runmarker B, Nerman O, Andersen O. The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset. J Neurol. 2015;262(5):1148–63.

    Article  PubMed  Google Scholar 

  50. Manouchehrinia A, Beiki O, Hillert J. Clinical course of multiple sclerosis: a nationwide cohort study. Mult Scler J. 2016:1352458516681197. doi:10.1177/1352458516681197. [Epub ahead of print]

  51. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci. 2003;206(2):135–7.

    Article  PubMed  Google Scholar 

  52. Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139(9):2395–405.

    Article  PubMed  Google Scholar 

  53. Tremlett H, Zhao Y, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler J. 2008;14(3):314–24.

    Article  Google Scholar 

  54. Skoog B, Tedeholm H, Runmarker B, Odn A, Andersen O. Continuous prediction of secondary progression in the individual course of multiple sclerosis. Mult Scler Rel Disord. 2014;3(5):584–92.

    Article  Google Scholar 

  55. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009;73(20):1616–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol. 2009;256(3):374–81.

    Article  PubMed  Google Scholar 

  57. Scalfari A, Lederer C, Daumer M, Nicholas R, Ebers G, Muraro P. The relationship of age with the clinical phenotype in multiple sclerosis. Mult Scler J. 2016;22(13):1750–8.

    Article  CAS  Google Scholar 

  58. Robertson NP, Clayton D, Fraser M, Deans J, Compston DA. Clinical concordance in sibling pairs with multiple sclerosis. Neurology. 1996;47(2):347–52.

    Article  CAS  PubMed  Google Scholar 

  59. Oturai AB, Ryder LP, Fredrikson S, et al. Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Mult Scler. 2004;10(1):5–8.

    PubMed  Google Scholar 

  60. Hensiek AE, Seaman SR, Barcellos LF, et al. Familial effects on the clinical course of multiple sclerosis. Neurology. 2007;68(5):376–83.

    Article  CAS  PubMed  Google Scholar 

  61. Koch M, Zhao Y, Yee I, et al. Disease onset in familial and sporadic primary progressive multiple sclerosis. Mult Scler J. 2010;16(6):694–700.

    Article  CAS  Google Scholar 

  62. Koch M, Uyttenboogaart M, Heerings M, Heersema D, Mostert J, De Keyser J. Progression in familial and nonfamilial MS. Mult Scler J. 2008;14(3):300–6.

    Article  Google Scholar 

  63. Ebers GC, Koopman WJ, Hader W, et al. The natural history of multiple sclerosis: a geographically based study. 8. Familial multiple sclerosis. Brain. 2000;123(3):641–9.

    Article  PubMed  Google Scholar 

  64. IMSGC. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–9.

    Article  Google Scholar 

  65. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–20.

    Article  CAS  PubMed  Google Scholar 

  66. CAMMS223 Trial Investigators, Coles AJ, Compston DAS, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–801.

    Article  Google Scholar 

  67. Cottrell DA, Kremenchutzky M, Rice GP, Hader W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain. 1999;122(4):641–7.

    Article  PubMed  Google Scholar 

  68. Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013;12:857–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK

    Katharine Harding & Neil Robertson

Authors
  1. Katharine Harding
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil Robertson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil Robertson .

Editor information

Editors and Affiliations

  1. Southmead Hospital, University of Bristol, Bristol, United Kingdom

    Alastair Wilkins

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Harding, K., Robertson, N. (2018). Epidemiology of Progressive Multiple Sclerosis. In: Wilkins, A. (eds) Progressive Multiple Sclerosis. Springer, Cham. https://doi.org/10.1007/978-3-319-65921-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-65921-3_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-65920-6

  • Online ISBN: 978-3-319-65921-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation